Clinical trial
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
NCT00936936 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 2, 2009
- Completion date
- January 11, 2024
- Enrollment
- 64 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
testicular cancer